BioCentury
ARTICLE | Clinical News

Viaskin Peanut: Phase II data

October 26, 2015 7:00 AM UTC

Top-line data from the open-label, international Phase II OLFUS-VIPES trial in 171 patients showed that once-daily 250 ug Viaskin Peanut patches for 24 months led to a desensitization rate of 70%. OLF...